ROSIGLITAZONE for endometriosis
ROSIGLITAZONE is a PPAR-gamma agonist listed as a Phase 2 clinical candidate for endometriosis per Open Targets.
Hypothesized mechanism
ROSIGLITAZONE activates PPAR-gamma, which may exert anti-inflammatory and anti-proliferative effects relevant to endometriotic lesion growth.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 3.8 of 10 overall, a emerging reading, from a pathway rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Only a single line of evidence is present: an Open Targets database entry indicating ROSIGLITAZONE is a PPAR-gamma agonist clinical candidate for endometriosis. No independent mechanistic lines (in-vitro, animal, or human pathway studies) converge in the verified claims.
Rigor
The claim derives from an Open Targets aggregation citing a PHASE_2 clinical stage for endometriosis, implying human-relevant context, but no actual study model, data, or results are provided. This is a database annotation rather than a primary mechanistic or clinical model, so rigor is limited.
Specificity
The claim names a precise molecular target and mechanism: ROSIGLITAZONE acts as a PPAR-gamma agonist on peroxisome proliferator activated receptor gamma. This is a highly specific, well-defined drug-target action.
Plausibility
PPAR-gamma agonism has a recognized anti-inflammatory/anti-proliferative rationale potentially relevant to endometriotic lesions, and the PHASE_2 designation supports a plausible target-phenotype fit. However, the verified claim provides no direct evidence linking PPAR-gamma modulation to endometriosis pathophysiology, so fit is only moderately supported.
Consistency
With only one claim there are no multiple mechanistic signals to compare; the single signal is internally coherent but provides no corroborating directionality. Consistency cannot be strongly established from a single database entry.
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX maps this drug and disease in its graph but returned no treat-score for the pair, which can mean the predicted link fell below the model's publication threshold.
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:50122 (drug) and MONDO:0005133 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), ROSIGLITAZONE (a Small molecule) is a clinical candidate for endometriosis (maximum clinical stage PHASE_2); its mechanism of action is Peroxisome proliferator-activated receptor gamma agonist on target peroxisome proliferator activated receptor gamma. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →